Białaczka włochatokomórkowa oporna na standardową terapię analogiem puryn – opis przypadku i przegląd piśmiennictwa

Hairy cell leukemia (HCL) is a rare, chronic lymphoproliferative disorder. Currently, purine nucleoside analogs (PNA) constitute the first line treatment of HCL. Cladribine could induce long lasting remission in majority of patients with only a single cycle of therapy. In fact the relapsed patients...

Full description

Saved in:
Bibliographic Details
Published inActa haematologica polonica Vol. 44; no. 3; pp. 340 - 343
Main Authors Grądzka, Klaudia, Kruczkowska-Tarantowicz, Kamila, Klimiuk, Marzenna B., Kłoczko, Janusz
Format Journal Article
LanguagePolish
Published Elsevier Sp. z o.o 01.07.2013
Subjects
analogi puryn
białaczka włochatokomórkowa
Hairy cell leukemia
Purine nucleoside analogs
Rituximab
rytuksymab
Rituximab
Hairy cell leukemia
Purine nucleoside analogs
analogi puryn
rytuksymab
białaczka włochatokomórkowa
Online AccessGet full text

Cover

More Information
Summary:Hairy cell leukemia (HCL) is a rare, chronic lymphoproliferative disorder. Currently, purine nucleoside analogs (PNA) constitute the first line treatment of HCL. Cladribine could induce long lasting remission in majority of patients with only a single cycle of therapy. In fact the relapsed patients could be treated successfully with cladribine too. Sometimes we observe the resistance to PNA. Rituximab and chemoimmunotherapy (rituximab plus cladribine) are effective in treatment of refractory HCL. We present a case of a 64-year-old man who was treated with rituximab after second progression of HCL. In March 2011, rituximab was given at a dose of 375mg/m2 i.v. once a week for eight weeks, with result of achievement of PR. During the last hospitalization in March 2013 the persistence of PR was confirmed.
ISSN:0001-5814
DOI:10.1016/j.achaem.2013.07.011